BIOMARKERcenter is First Comprehensive and Quality Assured Biomarker
Solution Available to the Pharmaceutical Industry
PHILADELPHIA and LONDON, June 17 /CNW/ -- Thomson Reuters, the world's
leading source of intelligent information for businesses and professionals,
announced today the launch of BIOMARKERcenter, a unique comprehensive resource
for biomarker intelligence. This new solution will be the first to provide the
pharmaceutical industry with a framework for assessing the potential of a
biomarker and to be alerted of any changes in their status.
BIOMARKERcenter covers the biomarkers identified in literature, patents,
conferences, clinical trial information, and other sources for all major
therapeutic areas: oncology, cardiovascular diseases, diabetes, respiratory
disorders, autoimmune diseases and neurological disorders. For each therapy
area, it includes not only biomarkers with established clinical usage, but
also emerging uses for the biomarker. Each record has been manually created by
a team of Thomson Reuters experts and provides a unique report on the
biomarker using a novel lifecycle model. Other data provided will include the
name, classification, biological entities/processes involved, associated
drugs, role or utilities, measurement techniques, regulatory status and
related diagnostic kits.
Biomarkers are measurable indicators which can be used to define a
biological state. Using Biomarkers as part of a pharmaceutical R&D program can
increase the success of the project by encouraging innovation, improving
efficiency, saving costs and delivering a valuable advantage over competitors.
"BIOMARKERcenter is the first reliable and comprehensive database of
biomarkers available to the pharmaceutical and diagnostic industries. It sets
a new standard for the presentation and analysis of Biomarker information,"
said Jon Brett-Harris, EVP Pharmaceutical and Chemicals Markets, Thomson
Reuters. "Biomarkers have the capacity to change the way pharmaceutical
companies develop drugs and bring them to the market. They allow companies to
improve their clinical trials design, and better understand the biology of the
diseases they are targeting, and we believe BIOMARKERcenter will become an
essential tool for our customers."
This new solution will be available through several delivery methods: a
standalone web solution, fully integrated into Prous Science's Integrity(R)
platform, or as an XML feed to internal customer databases. The Integrity
integration and XML feed are available currently, with the standalone solution
to be delivered later in 2008.
For further information about BIOMARKERcenter, please go to:
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals. We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare and
media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs more than 50,000 people in 93 countries. For more
information, go to www.thomsonreuters.com.
For further information:
For further information: Eoin Bedford, +44(0)2074334691,
firstname.lastname@example.org, or Sue Besaw, +1-215-823-1840
email@example.com, both of Scientific, for Thomson Reuters Web Site: